anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
FIELD: biotechnology, medicine, pharmacy. SUBSTANCE: recombinant protein Asp-pallidipin is bound by peptide bond with Asp by N-end of pallidipin. Recombinant protein is able to inhibit collagen- induced aggregation of mammalian platelets. Protein is prepared by culturing Escherichia coli strain transformed with vector comprising DNA that encodes Asp-pallidipin. Protein is purified by chromatography methods. Invention ensures to obtain a medicinal agent used for treatment of atherosclerotic or thrombotic diseases and cancer with metastatic tumor cells. Invention can be used for preparing an inhibitor of collagen- induced aggregation of platelets in mammals. EFFECT: improved method of production, valuable medicinal properties. 11 cl, 3tbl, 6 ex
A system for capture of dose delivery information is provided. The system includes a medication delivery device, a dose information capture device adapted to be attached to the medication delivery device, and a target element adapted to be attached to the medication delivery device. The target element comprises a magnet or ferrous element and the target element attaches to the medication delivery device on a dose delivery mechanism of the medication delivery device. The dose information capture device includes a magnetic position sensor adapted to detect a position of the target element. As an alternative to magnetic sensing, MEMS flow sensors, and the like may also be used. Exemplary systems preferably transmit dose information in real time to remote devices for further processing.
PURPOSE:To prepare the titled composition capable of preventing the dental carries and periodontosis, and useful as an ingredient of tooth paste, troche, etc., by using an organic solvent extract of a crude drug selected from the flower or rhizoma of arnica, fruit of cardamon, ZENKO, CHOSEN-NINJIN (root of Panax ginseng C.A. meyer) and KYOKATSU (rhizoma of Notopterygium incisium Ting), as an active component. CONSTITUTION:One or more crude drugs selected from arnica, cardamon, ZENKO, CHOSEN-JINJIN, and KYOKATSU, are extracted with an organic solvent, e.g. a polar solvent such as lower alcohol (methanol, ethanol, etc.), acetone, ethyl ether, etc., and a non-polar solvent such as benzene, hexane, etc., and the extract is used as a component of the titled composition. The amount of the extract is pref. 0.001- 5%, esp. 0.005-2%, based on the whole composition for oral cavity application.
A surface structural protein of Hepatitis A Virus (HAV) has been isolated and characterized from virus grown in tissue culture. This 33,000 dalton viral protein (VP-1) reacts with immune HAV sera and monoclonal antibodies that neutralize HAV infectivity. The VP-1 is usable for the preparation of a polypeptide subunit vaccine for HAV. Hybridoma cells were made which produced monoclonal antibodies to HAV or VP-1. These monoclonal antibodies were found to neutralize the infectivity of HAV and to compete with polyclonal antibody derived from human HAV immune sera. The monoclonal antibodies are useful for the neutralization of infectious HAV, the detection of antibodies to neutralizing sites on HAV, and the diagnoses of HAV disease in humans and other susceptible hosts.
An ultrasonic mixing system having a treatment chamber in which at least two separate phases can be mixed to prepare an emulsion is disclosed. Specifically, at least one phase is a dispersed phase and one phase in a continuous phase. The treatment chamber has an elongate housing through which the phases flow longitudinally from a first inlet port and a second inlet port, respectively, to an outlet port thereof. An elongate ultrasonic waveguide assembly extends within the housing and is operable at a predetermined ultrasonic frequency to ultrasonically energize the phases within the housing. An elongate ultrasonic horn of the waveguide assembly is disposed at least in part intermediate the inlet and outlet ports, and has a plurality of discrete agitating members in contact with and extending transversely outward from the horn intermediate the inlet and outlet ports in longitudinally spaced relationship with each other. The horn and agitating members are constructed and arranged for dynamic motion of the agitating members relative to the horn at the predetermined frequency and to operate in an ultrasonic cavitation mode of the agitating members corresponding to the predetermined frequency and the phases being mixed in the chamber.
BACKGROUND: The purpose of the study was to compare the efficacy of the use of 0.2% chlorhexidine irrigation and the oral antibiotics for the prevention of postoperative complication like pain, trismus, swelling and infection after the surgical extraction of IMTM.
MATERIAL AND METHODS: A randomised, double blinded clinical trial was planned with two equal groups. Patients were randomly divided into two groups using computer-generated codes with an allocation ratio of 1:1. Group I (Control): Standard preoperative and postoperative systemic oral antibiotics and Group II (Study): No systemic antibiotics and Chlorhexidine irrigation local delivery. The primary outcomes evaluated were postoperative pain, mouth opening, swelling and infection. The secondary outcome variables were the number of analgesics and antibiotics taken by the patient in the postoperative period, the satisfaction of the patient and adverse events, were followed up regulary for 7 days postoperatively.
RESULTS: A total of 84 patients, divided into two equal groups participated in the study. In intergroup comparison of swelling, the difference was non-significant on postoperative day (POD) 1 and 7, except for POD 3, where it showed significantly lower results in the antibiotic group (p = 0.012). However, there was no significant difference in pain found between both groups at any of the postoperative time points, and the study group had a lesser need for rescue analgesics than the control group. A statistically significant difference in incidence of dry socket was observed (p = 0.03) and gastrointestinal adverse symptoms, but it showed insignificant results for wound dehiscence and pus discharge. Also, patient satisfaction was higher in the study group.
CONCLUSIONS: both antibiotics and localised delivery demonstrated comparable results in terms of swelling, pain and trismus. However, with lesser adverse events, the localised chlorhexidine delivery with curved tips outperformed the antibiotic group.
HIV is most commonly transmitted via a mucosal surface. The mucosal lining is a potential site of both humoral and cellular protection through the activity of B lymphocytes, activated memory T lymphocytes, secretory IgA, and antigen presenting cells. In addition to systemic immunity, a preventive HIV vaccine should induce immune responses at the mucosal surfaces that are portals of HIV entry into the body.

Targeted lymph node immunization involves vaccine injection into the subcutaneous tissue near a lymph node. This strategy has proven effective in the simian immunodeficiency virus (SIV)/rhesus macaque model. The iliac and inguinal lymph nodes in the groin are the primary draining lymph nodes of the genitourinary and rectal tracts. This study will evaluate and compare the safety and immunogenicity of ALVAC-HIV (vCP205) when administered subcutaneously in the groin and intramuscularly in the deltoid region. ALVAC-HIV (vCP205) is a canarypox virus vector vaccine expressing portions of the gp120, Gag, and Pol genes.

Participants in this study will be randomly assigned to receive vaccine or placebo injections in the groin area or the upper arm. All participants will have three baseline visits for blood tests and sigmoidoscopies to measure baseline immune functions. After these visits, participants will receive weekly injections for 4 weeks. Groin injections will be given subcutaneously (under the skin) and upper arm injections will be given intramuscularly (into the muscle). Participants will have follow-up visits 5 and 11 months after the last immunization. Participants will have blood draws and sigmoidoscopies and will receive HIV risk reduction counseling throughout the study. Total length of participation will be approximately 14 months. Participants may continue to contact the study for HIV testing and study-related concerns for 1 year after study participation.
cBBR T cells in which a 4-1BB/CD3ζ (cBBR) fusion protein or a variant thereof is overexpressed in T cells specifically kill cancer cells in which 4-1BBL is overexpressed. Compared to cBBR T cells comprising a native form 4-1BB extracellular domain, the T cells, in which cBBR is overexpressed, comprising a 4-1BB extracellular domain variant have lower binding to 4-1BBL and cytotoxicity. If stimulated by Urelumab, the cBBR T cells, in which cBBR is overexpressed, comprising the variant have remarkably better activity than normal T cells. Furthermore, if reacted with an anti-BCMA/ anti-4-1BB bispecific antibody, the T cells show remarkably better killing activity, on cancer cells in which BCMA is expressed, than normal T cells. Therefore, T cells in which the cBBR fusion protein is overexpressed can be used as an anticancer agent. In addition, since it has been identified that NK cells in which a cBBR fusion protein is overexpressed are effectively activated by an anti-4-1BB antibody, it has been identified that the NK cells in which a cBBR fusion protein is overexpressed can be used as an anticancer agent.
Previously, we reported an anti-inflammatory effect of mTORC1 in a mouse model of type 2 skin inflammation. TSLP, one of the epithelial cell-derived cytokines, was upregulated by Raptor deficiency or rapamycin treatment, which was inhibited by dimethyloxalylglycine (DMOG). However, it remains unclear how DMOG regulates TSLP expression and type 2 skin inflammation. In this study, we investigated the protective effect of DMOG on MC903 (calcipotriol)-induced type 2 skin inflammation. Morphological and immunological changes were assessed by H-E staining, flow cytometry and RT-qPCR. DMOG treatment attenuated MC903-induced skin inflammation in a T cell-independent manner. The anti-inflammatory effect of DMOG was accompanied by downregulation of TSLP and IL-33, and supplementation with recombinant TSLP and IL-33 abolished the effect of DMOG. MC903 increased ROS levels in skin tissue, which was prevented by DMOG. Furthermore, the ROS scavenger N-acetylcysteine (NAC) downregulated TSLP and ameliorated MC903-induced skin inflammation, as did DMOG. Finally, the effect of DMOG on ROS and TSLP was reduced by HIF knockdown. These results suggest that DMOG downregulates TSLP and ROS through the HIF pathway, which reduces MC903-induced skin inflammation.
Umbilical hernia and cholelithiasis are quite common in general surgical practice. The coexistence of cholelithiasis and umbilical hernia has been previously reported in the literature. However, most of the publications on this subject are retrospective series, and the prevalence of cholelithiasis in patients with umbilical hernia and the risk factors of umbilical hernia in patients with cholelithiasis have not been investigated prospectively to date. This study aims to fill this gap by providing prospective data on the prevalence and risk factors associated with the coexistence of these conditions.

Researchers aim to determine the exact prevalence and risk factors for the association of gallstones and umbilical hernia. Umbilical hernia is defined according to the European Hernia Society Classification for primary and incisional abdominal wall hernias as hernias occurring from 3 cm above to 3 cm below the umbilicus. The main outcome measures are the presence of gallstones in patients presenting with umbilical hernia and the presence of umbilical hernia in patients diagnosed with gallstones. Patients with umbilical hernia are examined with biliary ultrasound, while patients with cholelithiasis are evaluated for umbilical hernia by physical examination and ultrasound. Factors such as age, gender, body mass index (BMI), family history, comorbidities, tobacco use, parity, and history of multiple pregnancy are analyzed as potential risk factors.
The goal of this SBIR is to test a novel mobile and text-based measurement and feedback system tailored to WSM. Investigators will recruit 10 care teams (50 care team members total: 10 managers/administrators, 10 supervisors, and 30 care coordinators), 30 caregivers, and 15 youth/young adults (14+ yo) with SED currently enrolled in WSM. Caregivers of minor children aged 5-17 and caregivers of young adults 18-26 will be invited to participate. However, only parents with youth aged 14-17 will be invited to consider participation for their children, as well, and young adults age 18-26 will have the opportunity to participate without a caregiver If a caregiver has multiple children enrolled in Wraparound, we will select one child to invite to participate. Of those eligible, investigators will select 30 caregivers and up to 15 youth/young adults (14+) that have access to a mobile device. These participants will be informed of the project by members of their care team and asked to complete a consent to contact if they are interested in learning more about the research study. Interested families will be asked to review consent materials and sign up online. Caregivers and youth/young adults will participate in a 30-minute study orientation meeting and then interact independently with the system over a 4-week period. During this time, care team members will have access to the SMART-Wrap website, where they can view the survey feedback from their families. Care team members will be expected to interact with the system throughout the test period and may adjust care based on the feedback they receive. Within 5 days of the last text message, caregivers and youth/young adults will complete a brief survey evaluating the prototype in the following areas of usability, acceptability, and feasibility, as well as complete the 10-item System Usability Survey (SUS). Care team members will complete a similar survey that asks about these same areas, but also includes items about compatibility with existing wraparound treatment planning and implementation, interoperability with existing electronic record management systems, duplicative vs. complementary with existing systems, and added value over existing methods. Following completion of their evaluation, participants will be invited to take part in 45-minute interviews or virtual focus groups (separately for care team members, caregivers, and youth/young adults). Of the participants that agree, 10 care team members, 10 caregivers, and 10 youth/young adults will be selected to complete the virtual focus group.
The invention belongs to the field of microbiology, and particularly relates to a pseudomonas aeruginosa phage YAPa with wide preferendum and application thereof. The preservation number is CGMCC (China General Microbiological Culture Collection Center) No.8951. It is verified that the phage has the splitting action to a type strain and is a double chain DNA (Deoxyribonucleic Acid). The length of the nucleotide sequence is 94588bp, and the phage belongs to siphoviridae. The head of the phage is about 100nm long, and the tail is about 405nm long. The phage is high in absorption efficiency to the host bacterium and great in splitting amount. Through further detection, the phage has the phagocytosis and splitting action to 44 pseudomonas aeruginosa of 42 genotypes. The phage provided by the invention is suitable for various practical purposes for phagocytosis and splitting decomposition of the pseudomonas aeruginosa according to good splitting property, absorption and wide preferendum. Products such as pharmaceutical compositions and environmental detergents which take the phage as one of the active components as well as use are required to be protected.
Spontaneous bacterial Peritonitis (SBP) in liver cirrhosis is a severe and increasingly common disease, which is associated with high morbidity, mortality and high costs for the investigator's health care system. In addition to age and severity of comorbidities, female sex is associated with detrimental outcome. Delayed diagnosis and therapy of SBP may lead to a higher mortality in this patient population. Therefore, an early diagnosis and adequate anti-infective therapy is essential. Due to the accumulation of antimicrobial-resistant (AMR) pathogens, especially in nosocomial SBP, empirical application of broad-spectrum antibiotics is recommended in the therapy of SBP.During the use of antibiotic drugs in general, pharmacokinetic/pharmacodynamic (PK/PD) targets, as the achieved time period over the minimal inhibitory concentration (MIC), should be evaluated to increase drug efficacy and reduce AMR development. Pharmacokinetic studies of meropenem concentrations at the infection site in this particular group of patients are rare in the literature. Recent studies in critically ill patients showed highly variable meropenem concentrations in peritoneal fluid after iv administration. The aim of this study is to determine the pharmacokinetics of meropenem during SBP in female and male patients with liver cirrhosis to investigate whether pharmacodynamics therapy goals are met.
Every group received routine traditional physiotherapy twice a week over the period of 4 weeks. This routine traditional treatment consisted of stretching, weight bearing, functional reaching, walking, and electrotherapy. Sessions were 40 minutes. The children in the taping group were taped 6 days per week for 4 weeks. The children were checked for allergies before applying the tape. A 5-cm tape was applied and kept in position for 3 days, and the region was then left to rest for 24 hours.
Therapeutic compsns. comprise a broad-spectrum antibiotic e.g. tetracyclines or chloramphenicol, and a culture of lactic bacilli resistant to the antibiotics, together with an enzyme diffusing-agent, esp. hyaluronidase or lysozyme. The antibiotics are less likely to induce side-effects due to their action on intestinal flora. Proteases may be used instead of the above enzymes. Pref. lactic bacilli are freeze-dried cultures of lactobacillus acidophilus made resistant to tetracyclines, penicillin, neomycin, chloramphenicol, erythromycin, cathomycin.
The invention provides a use of sodium bicarbonate in preparation of medicines for treating cancer. The molecular formula of sodium bicarbonate is NaHCO3. Researches verify that sodium bicarbonate induces neoplasm necrosis or inhibit tumor growth, has the effect of inhibiting tumor angiogenesis and can be used to prepare medicines for tumor transarterial embolization and tumor transarterial chemoembolization, especially medicines for artery chemoembolization of liver cancer. Researches show that the curative effect of sodium bicarbonate combined in use with tumor transarterial chemoembolization or tumor transarterial embolization is remarkably greater than single use of sodium bicarbonate or tumor transarterial chemoembolization or tumor transarterial embolization. The dosing form of the medicine is injection. The invention develops novel use of sodium bicarbonate in preparation of medicines for treating cancer, the medicine is a medicine which is delivered to the tumor body and is free from toxicity to human body, and the treatment price can be lowered.
BACKGROUND: Experimental animal models of ischemic spinal cord injury (iSCI) are essential for studying its pathogenesis and for developing new therapeutic strategies to improve functional recovery in humans. Many existing models, however, exhibit high variability or early lethality. A reliable experimental iSCI model would significantly advance novel treatment approaches for these severe neurological disorders. To this end, we have established a rat model of persistent iSCI with an extended lifespan.
METHODS: We have developed a novel iSCI model that induces localized ischemic lesions in the spinal cord of male Sprague-Dawley rats. This is achieved by cross clamping the descending aorta just rostral the azygos vein using an atraumatic bulldog clamp.
RESULTS: The experimental iSCI model consistently demonstrated symptoms specific to spinal cord ischemia at the lumbar level. The procedure takes approximately 50 min and does not require specialized surgical equipment. It has a survival rate of 84%, a recovery rate of 40%, and a complication rate of 16%.
CONCLUSIONS: We have successfully developed a rat model of persistent iSCI. This protocol proves to be highly reliable and holds promise for evaluating new therapeutic strategies aimed at promoting functional recovery in patients suffering from spinal cord ischemia.
An indexing system uses a cascade of hash structures to process data entries upon ingest for indexing. The indexing system may be used for enhancing database privacy, anonymization, or data compression. A hash structure, for example, a bloom filter or hash table, passes a representation of the data entries to a subsequent hash structure in the cascade responsive to determining that the hash structure previously filtered an instance of the same representation. The indexing system can generate the representations of the data entries using one or more hash functions. A terminal hash structure of the cascade may index the data entries responsive to determining that the data entries satisfy a criteria for anonymization. For instance, the indexing system determines that there exists a threshold number of data entries describing a population of subjects having the same combination of data elements.
Novel compounds of the formula <FORM:1068751/C2/1> where R1 and R2 are each C1- 8 alkyl alkenyl alkoxy alkenyloxy, or alkylmercapto, hydroxy, halogen, CF3, or -OANR3R4, where A is C2- 6 alkylene and R3 and R4 are each C1- 8 alkyl or are alkyl linked together to form a 5 to 7 ring atom saturated heterocyclic group, X and Y are 0 to 4 and n is 1 or 2, the alkali metal salts thereof and the pharmacologically acceptable acid addition salts and quaternary ammonium salts when at least one of R1 and R2 is -OANR3R4 are prepared by reacting a cyclic ketone and Grignard reagent of formulae <FORM:1068751/C2/2> in the presence of an inert organic solvent, and hydrolysing the tetrahydropyranyl ether formed with mineral acid.  When n = 1, the indonones may be made by the HF-catalysed cyclization of an a -benzyl phenylacetic acid, which may be prepared from a phenylacetic acid and a benzylhalide in the presence of potassium amide. When n = 2, the a -tetralones may be prepared by HF-catalysed cyclization of 2,4-diphenyl butyric acid obtained by the Clemmensen reduction of the 3-ketoacid.  This 3-ketoacid is produced by hydrolysis of the corresponding cyanide, which is produced by addition of HCN to a chalcone obtained from acetophenone and benzaldehyde in the presence of a base, e.g. NaOH or KOH in an inert solvent.  Pharmaceutical preparations having anti-fertility, anti-inflammanary and antimienobial properties and stimulating the central nervous system contain the above compounds of Formula I with conventional diluents and carriers.
Systems, methods and apparatus for genital and anal pre-cancer treatment and the treatment of cervical intraepithelial neoplasia are disclosed. One aspect includes an applicator for topically applying a therapeutic agent. The applicator includes a container to store the therapeutic agent. The applicator further includes an actuator configured to release the therapeutic agent from the container. The applicator further includes a tip configured to absorb the therapeutic agent released from the container, the tip further configured to release the therapeutic agent to a treatment area in response to contact between the tip and the treatment area. Another aspect includes an applicator for applying a film containing therapeutic material.
Noninvasive ventilation (NIV) will be initiated and managed as per current standard of practice guided by the American Academy of Neurology (AAN) Practice Parameters (updated in 2009), in all subjects with amyotrophic lateral sclerosis (ALS) and a forced vital capacity of \<50% predicted. Sleep studies will be performed at baseline, 2 weeks, 1, 3 and 6 months, but will not influence management of the NIV.